Otsuka And Lundbeck Announce U.S. FDA Approval Of Supplemental New Drug Application For Rexulti® (Brexpiprazole) For The Treatment Of Agitation Associated With Dementia Due To Alzheimer’s Disease
11/05/2023 03:48
May 11 (Reuters) - Otsuka Holdings Co Ltd 4578.T :
* OTSUKA HOLDINGS CO LTD - OTSUKA AND LUNDBECK ANNOUNCE U.S.
FDA
APPROVAL OF SUPPLEMENTAL NEW DRUG APPLICATION FOR REXULTI®
(BREXPIPRAZOLE) FOR THE TREATMENT OF AGITATION ASSOCIATED WITH
DEMENTIA DUE TO ALZHEIMER’S DISEASE
Source text for Eikon: ID:nTSqk8a098
Further company coverage: 4578.T
(Reporting by Eimi Yamamitsu)
((Eimi.Yamamitsu@thomsonreuters.com;))
Recent news on H Lundbeck A/S
See all newsEurope Research Roundup: BAWAG Group, Enka Insaat, Partners Group Holding
Brief: CMS Announces Selection Of Drugs For Third Cycle Of The Medicare Drug Price Negotiation Program
Europe Research Roundup: BNP Paribas, Swedbank, Volkswagen
H Lundbeck steps down from takeover for Avadel, shares rise 3%
Brief: H Lundbeck A/S Says Noted That Our Offer For Acquiring Avadel No Longer Is Considered Superior By Their Board, We Are Currently Considering Our Options